The Medical Advisor

Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem Cel...

Abstract Background: Stage 4 cancer — defined by metastatic spread beyond the original tumor site — has a poor prognosis with conventional treatment alone. There is growing interest in repurposed antiparasitic drugs such as ivermectin , fenbendazole , and mebendazole for potential antineoplastic effects. Preclinical research suggests mechanisms including disruption of oncogenic signaling pathways and inhibition of cancer cell proliferation and survival, but controlled clinical evidence in humans remains limited. Objective: To summarize and characterize a large compilation of anecdotal clinical case reports describing the use of ivermectin, fenbendazole, and mebendazole in individuals with Stage 4 cancers (various tumor types) and to highlight reported outcomes and therapeutic contexts. Methods: Over 320 individual case reports were aggregated from public sources — predominantly social media posts, practitioner-shared testimonials, and independently published patient narratives....